American Journal of Kidney Diseases
Volume 41, Issue 4 , Pages 833-839 , April 2003

Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis

  • Jiro Takaki, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Jiro Takaki, MD, Department of Psychosomatic Medicine, Tokyo University Hospital, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
    • Department of Psychosomatic Medicine, Faculty of Medicine, University of Tokyo, TokyoJapan
    • ,
  • Tadahiro Nishi, MD

      Affiliations

    • Nishi Clinic, TokyoJapan
    • ,
  • Masaomi Nangaku, MD

      Affiliations

    • Division of Nephrology and Endocrinology, Faculty of Medicine, the University of Tokyo, TokyoJapan
    • ,
  • Hiromi Shimoyama, MD

      Affiliations

    • Yuuai Clinic, Saitama, Japan
    • ,
  • Toshio Inada, MD

      Affiliations

    • Bousei Tanashi Clinic, TokyoJapan
    • ,
  • Norimasa Matsuyama, MD

      Affiliations

    • Tokyo Kensei Hospital, TokyoJapan
    • ,
  • Hiroaki Kumano, MD

      Affiliations

    • Department of Psychosomatic Medicine, Faculty of Medicine, University of Tokyo, TokyoJapan
    • ,
  • Tomifusa Kuboki, MD

      Affiliations

    • Department of Psychosomatic Medicine, Faculty of Medicine, University of Tokyo, TokyoJapan

Received 27 June 2002 ,Revised 26 November 2002 ,Accepted 26 November 2002.

References 

  1. Tan EK, Ondo W. Restless legs syndrome (Clinical features and treatment). Am J Med Sci. 2000;319:397–403
  2. Collad-Seidel V, Kohnen R, Samtleben W, Hillebrand GF, Oertel WH, Trenkwalder C. Clinical and biochemical findings in uremic patients with and without restless legs syndrome. Am J Kidney Dis. 1998;31:324–328
  3. O’Keeffe ST. Restless legs syndrome, a review. Arch Intern Med. 1996;156:243–248
  4. Janzen L, Rich JA, Vercaigne LM. An overview of levodopa in the management of restless legs syndrome in a dialysis population (Pharmacokinetics, clinical trials, and complications of the therapy). Ann Pharmacother. 1999;33:86–92
  5. Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis. 2001;38:104–108
  6. Winkelman JW, Chertow GM, Lazarus JM. Restless legs syndrome in end-stage renal disease. Am J Kidney Dis. 1996;28:372–378
  7. Roger SD, Harris DC, Stewart JH. Possible relation between restless legs and anemia in renal dialysis patients. Lancet. 1991;337:1551; (letter)
  8. Miranda M, Araya F, Castillo JL, Duran C, Gonzalez F, Aris L. Restless legs syndrome (A clinical study in adult general population and in uremic patients). Rev Med Chil. 2001;129:179–186
  9. Walters AS  International Restless Legs Syndrome Study Group . Toward a better definition of the restless legs syndrome. Mov Disord. 1995;10:634–642
  10. Trenkwalder C, Stiasny K, Pollmacher T, et al.  l-Dopa therapy of uremic and idiopathic restless legs syndrome (A double-blind, crossover trial). Sleep. 1995;18:681–688
  11. Walker SL, Fine A, Kryger MH. l-Dopa/carbidopa for nocturnal movement disorders in uremia. Sleep. 1996;19:214–218
  12. Ausserwinkler M, Schmidt P. Successful clonidine treatment of restless legs syndrome in chronic kidney insufficiency. Schweiz Med Wochenschr. 1989;119:184–186
  13. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361–370
  14. Zigmond AS, Snaith PR. Hospital Anxiety and Depression Scale (HAD shakudo). Kitamura T, translator. Seishinka-shindangaku. 1993;4:371–372
  15. Higashi A, Yashiro H, Kiyota K, et al.  [Validation of the Hospital Anxiety and Depression Scale in a gastro-intestinal clinic.]. Nippon Shokakibyo Gakkai Zasshi. 1996;93:884–892
  16. Hatta H, Higashi A, Yashiro H, et al.  A validation of the Hospital Anxiety and Depression Scale. Jpn J Psychosom Med. 1998;38:309–315
  17. Endler NS, Parker JDA. In: Coping Inventory for Stressful Situations (CISS) Manual. Toronto, Canada: Multi-Health Systems; 1990;p. 1–38
  18. Endler NS, Kantor L, Parler JDA. State-trait coping, state-trait anxiety and academic performance. Pers Individ Dif. 1994;16:663–670
  19. Furukawa T, Suzuki-Moor A, Saito Y, Hamanaka T. Reliability and validity of the Japanese version of the Coping Inventory for Stressful Situations (A contribution to the cross-cultural studies of coping). Psychiatr Neurol Jpn. 1993;95:602–621
  20. Daugirdas JT. Second-generation logarithmic estimates of single-pool variable volume of Kt/V (An analysis error). J Am Soc Nephrol. 1993;4:1205–1213
  21. Cohen J. A coefficient of agreement of normal scales. Educ Psychol Meas. 1960;20:37–46
  22. Cronbach LJ, Warrington WG. Time-limit tests (Estimating their reliability and degree of speeding). Pschometrica. 1951;16:167–188
  23. Virga G, Mastrosinome S, Amici G, Munaretto G, Gastaldon F, Bonadonna A. Symptoms in hemodialysis patients and their relationship with biochemical and demographic parameters. Int J Artif Organs. 1998;21:788–793
  24. Hui DS, Wong TY, Ko FW, et al.  Prevalence of sleep disturbances in Chinese patients with end-stage renal failure on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 2000;36:783–788
  25. Huiqi Q, Shan L, Mingcai Q. Restless legs syndrome (RLS) in uremic patients is related to the frequency of hemodialysis session. Nephron. 2000;86:540; (letter)
  26. Lavine GL, Lobbezoo F, Rompe PH, et al.  Cigarette smoking as a risk factor or an exacerbating factor for restless legs syndrome and sleep bruxism. Sleep. 1997;20:290–293
  27. Allen RP, Earley CJ. Restless legs syndrome (A review of clinical and pathophysiologic features). J Clin Neurophysiol. 2001;18:128–147
  28. Berndt TJ, Liang M, Tyce GM, Knox FG. Intrarenal serotonin, dopamine, and phosphate handling in remnant kidneys. Kidney Int. 2001;59:625–630
  29. Berndt TJ, Tucker RR, Kent PD, Streiff PC, Tyce GM, Knox FG. Dopamine enhances phosphaturic effect of PTH during acute respiratory alkalosis. J Lab Clin Med. 1999;134:616–622
  30. de Toled FG, Thompson MA, Bolliger C, Tyce GM, Dousa TP. Gamma-l-glutamyl-l-dopa inhibits Na(+)-phosphate cotransport across renal brush border membranes and increases renal excretion of phosphate. Kidney Int. 1999;55:1832–1842
  31. Ekbom KA. Restless legs syndrome. Neurology. 1960;10:868–873
  32. Levin NW, Heonich NA. Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients. Curr Opin Nephrol Hypertens. 2001;10:563–568
  33. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients (Recommendations for a change in management). Am J Kidney Dis. 2000;35:1226–1237
  34. Llach F. Hyperphosphatemia in end-stage renal disease patients (Pathophysiological consequences). Kidney Int Suppl. 1999;73:S31–S37
  35. Ulfberg J, Nystrom B, Carter N, Edling C. Prevalence of restless legs syndrome among men aged 18 to 64 years (An association with somatic disease and neuropsychiatric symptoms). Mov Disord. 2001;16:1159–1163
  36. Saletu M, Anderer P, Satelu B, Lindeck-Pozza L, Hauer C, Satelu-Zyhlarz G. EEG mapping in patients with restless legs syndrome as compared with normal controls. Psychiatry Res Neuroimaging. 2002;115:49–61
  37. Bankko K, Delaive K, Walld R, Kryger MH. Restless legs syndrome in 218 patients (Associated disorders). Sleep Med. 2000;1:221–229
  38. Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K. Prevalence and risk factors of RLS in an elderly population (The MEMO study. Memory and morbidity in Augsberg elderly). Neurology. 2000;54:1064–1068
  39. Scharf MB, Brown L, Hirschowitz J. Possible efficacy of alprazolam in restless legs syndrome. Hillside J Clin Psychiatry. 1986;8:214–223
  40. Saletu M, Anderer P, Saletu-Zyhlarz G, et al.  Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) (Acute placebo-controlled sleep laboratory studies with clonazepam). Euro Neuropsychopharmacol. 2001;11:153–161
  41. Figgitt DP, McClellan KJ. Fluvoxamine (An update review of its use in the management of adults with anxiety disorders). Drugs. 2000;60:925–954
  42. Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL. Paroxetine (An update of its use in psychiatric disorders in adults). Drugs. 2002;62:655–703
  43. Pande AC, Pollack MH, Crokatto J, et al.  Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000;20:467–471
  44. Pande AC, Davidson JR, Jefferson JM, et al.  Treatment of social phobia with gabapentin (A placebo-controlled study). J Clin Psychopharmacol. 1999;19:341–348
  45. Dimmit SB, Riley GJ. Selective serotonin reuptake inhibitors can reduce restless legs syndrome. Arch Intern Med. 2000;160:712; (letter)
  46. Happe S, Klosch G, Saletu S, Zeitlhofer J. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology. 2001;57:1717–1719
  47. Hargrave R, Beckley DJ. Restless legs syndrome exacerbated by sertraline. Psychosomatics. 1998;39:177–178
  48. Boghen D, Lamothe L, Elie R, Godbout R, Montplaisir J. The treatment of the restless legs syndrome with clonazepam (A prospective controlled study). Can J Neurol Sci. 1986;13:245–247
  49. Testad W, Sorensen O, Larsen S, Lillevold PE, Stensrud P, Nyberg-Hansen R. Treatment of the restless legs syndrome with carbamazepine (A double blind study). BMJ. 1984;288:443–446
  50. Davis BJ, Rajput A, Rajput ML, Aul EA, Eichhorn GR. A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol. 2000;43:70–75
  51. Chaput de Saintonge DM, Herxheimer A. Harnessing placebo effects in health care. Lancet. 1994;344:995–998
  52. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research (Conceptual, strategic, and statistical considerations). J Pers Soc Psychol. 1986;51:1173–1182
  53. Bolger N. Coping as a personality process (A prospective study). J Pers Soc Psychol. 1990;59:525–537
  54. Suls J, David JP. Coping and personality (Third time’s the charm?). J Pers. 1996;64:993–1005

PII: S0272-6386(03)00031-3

American Journal of Kidney Diseases
Volume 41, Issue 4 , Pages 833-839 , April 2003

Article Tools